It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Background
The ALS Functional Rating Scale in its revised version (ALSFRS-R) is a disease-specific severity score that reflects motor impairment and functional deterioration in people with amyotrophic lateral sclerosis (ALS). It has been widely applied in both clinical practice and ALS research. However, in Germany, several variants of the scale, each differing slightly from the others, have developed over time and are currently in circulation. This lack of uniformity potentially hampers data interpretation and may decrease item validity. Furthermore, shortcomings within the standard ALSFRS-R questions and answer options can limit the quality and conclusiveness of collected data.
Methods
In a multistage consensus-building process, 18 clinical ALS experts from the German ALS/MND network analyzed the ALSFRS-R in its current form and created an adapted, annotated, and revised scale that closely adheres to the well-established standardized English version.
Results
Ten German-language variants of the ALSFRS-R were collected, three of which contained instructions for self-assessment. All of these variants were compiled and a comprehensive linguistic revision was undertaken. A short introduction was added to the resulting scale, comprising general instructions for use and explanations for each of the five reply options per item. This adapted version of the scale, named ALSFRS-R-SE (with the “SE” referring to “self-explanatory”), was carefully reviewed for language and comprehensibility, in both German and English.
Conclusion
An adapted and annotated version of the ALSFRS-R scale was developed through a multistage consensus process. The decision to include brief explanations of specific scale items and reply options was intended to facilitate ALSFRS-R-SE assessments by both healthcare professionals and patients. Further studies are required to investigate the accuracy and utility of the ALSFRS-R-SE in controlled trials and clinical real-world settings.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
2 Universitätsklinikum Münster, Department of Neurology, Münster, Germany (GRID:grid.16149.3b) (ISNI:0000 0004 0551 4246); UKM-Marienhospital Steinfurt, Department of Medicine, Steinfurt, Germany (GRID:grid.16149.3b)
3 LMU Klinikum, Ludwig-Maximilians-Universität München, Friedrich-Baur-Institut und Neurologische Klinik und Poliklinik, Munich, Germany (GRID:grid.411095.8) (ISNI:0000 0004 0477 2585)
4 Universitätsklinikum Ulm, Klinik für Neurologie, Ulm, Germany (GRID:grid.410712.1) (ISNI:0000 0004 0473 882X)
5 Hannover Medical School, Department of Neurology, Hannover, Germany (GRID:grid.10423.34) (ISNI:0000 0000 9529 9877)
6 Universitätsmedizin Schleswig-Holstein, Department of Neurology, Campus Lübeck, Lübeck, Germany (GRID:grid.412468.d) (ISNI:0000 0004 0646 2097)
7 Universitätsklinikum Leipzig, Department of Neurology, Leipzig, Germany (GRID:grid.411339.d) (ISNI:0000 0000 8517 9062)
8 Klinikum rechts der Isar, Technical University Munich, Department of Neurology, Munich, Germany (GRID:grid.15474.33) (ISNI:0000 0004 0477 2438)
9 Universitätsklinikum Würzburg, Department of Neurology, Würzburg, Germany (GRID:grid.411760.5) (ISNI:0000 0001 1378 7891)
10 University Hospital Carl Gustav Carus, Technische Universität Dresden, Department of Neurology, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); Research Site Dresden, DZNE, German Center for Neurodegenerative Diseases, Dresden, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426)
11 Universitätsmedizin Essen, Klinik für Neurologie und Center for Translational Neuro- and Behavioral Science, Essen, Germany (GRID:grid.477805.9) (ISNI:0000 0004 7470 9004)
12 Alfried Krupp Krankenhaus, Department of Neurology, Centre for ALS and Other Motor Neuron Disorders, Essen, Germany (GRID:grid.476313.4)
13 Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany (GRID:grid.476313.4)
14 Universitätsklinikum Ulm, Klinik für Neurologie, Ulm, Germany (GRID:grid.410712.1) (ISNI:0000 0004 0473 882X); German Centre for Neurodegenerative Diseases, Research Site Ulm, DZNE, Ulm, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426)
15 Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neurology, Center for ALS and Other Motor Neuron Disorders, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662); Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany (GRID:grid.6363.0)